BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 30132517)

  • 21. Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients.
    Heestand GM; Schwaederle M; Gatalica Z; Arguello D; Kurzrock R
    Eur J Cancer; 2017 Sep; 83():80-87. PubMed ID: 28728050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy.
    Fountzilas G; Valavanis C; Kotoula V; Eleftheraki AG; Kalogeras KT; Tzaida O; Batistatou A; Kronenwett R; Wirtz RM; Bobos M; Timotheadou E; Soupos N; Pentheroudakis G; Gogas H; Vlachodimitropoulos D; Polychronidou G; Aravantinos G; Koutras A; Christodoulou C; Pectasides D; Arapantoni P
    J Transl Med; 2012 Jan; 10():10. PubMed ID: 22240029
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Proliferation and invasion of colon cancer cells are suppressed by knockdown of TOP2A.
    Zhang R; Xu J; Zhao J; Bai JH
    J Cell Biochem; 2018 Sep; 119(9):7256-7263. PubMed ID: 29761838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer.
    Arriola E; Rodriguez-Pinilla SM; Lambros MB; Jones RL; James M; Savage K; Smith IE; Dowsett M; Reis-Filho JS
    Breast Cancer Res Treat; 2007 Dec; 106(2):181-9. PubMed ID: 17260090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer.
    de Resende MF; Vieira S; Chinen LT; Chiappelli F; da Fonseca FP; Guimarães GC; Soares FA; Neves I; Pagotty S; Pellionisz PA; Barkhordarian A; Brant X; Rocha RM
    J Transl Med; 2013 Feb; 11():36. PubMed ID: 23398928
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bromodomain and hedgehog pathway targets in small cell lung cancer.
    Kaur G; Reinhart RA; Monks A; Evans D; Morris J; Polley E; Teicher BA
    Cancer Lett; 2016 Feb; 371(2):225-39. PubMed ID: 26683772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RHPN1‑AS1 promotes ovarian carcinogenesis by sponging miR‑6884‑5p thus releasing TOP2A mRNA.
    Cui S; Li F
    Oncol Rep; 2021 Oct; 46(4):. PubMed ID: 34414458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DNA topoisomerase II alpha promotes the metastatic characteristics of glioma cells by transcriptionally activating β-catenin.
    Liu Y; Ma J; Song JS; Zhou HY; Li JH; Luo C; Geng X; Zhao HX
    Bioengineered; 2022 Feb; 13(2):2207-2216. PubMed ID: 35012441
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Untangling trapped topoisomerases with tyrosyl-DNA phosphodiesterases.
    Zagnoli-Vieira G; Caldecott KW
    DNA Repair (Amst); 2020 Oct; 94():102900. PubMed ID: 32653827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. RRM1, TUBB3, TOP2A, CYP19A1, CYP2D6: Difference between mRNA and protein expression in predicting prognosis of breast cancer patients.
    Xu YC; Zhang FC; Li JJ; Dai JQ; Liu Q; Tang L; Ma Y; Xu Q; Lin XL; Fan HB; Wang HX
    Oncol Rep; 2015 Oct; 34(4):1883-94. PubMed ID: 26252353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic Significance of DNA Topoisomerase II Alpha (TOP2A) in Cholangiocarcinoma.
    Ong KH; Lai HY; Sun DP; Chen TJ; Huang SK; Tian YF; Chou CL; Shiue YL; Chan TC; Li CF; Kuo YH
    Front Biosci (Landmark Ed); 2023 Apr; 28(4):75. PubMed ID: 37114547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantum dot-based immunofluorescent imaging and quantitative detection of TOP2A and prognostic value in triple-negative breast cancer.
    Zheng H; Li X; Chen C; Chen J; Sun J; Sun S; Jin L; Li J; Sun S; Wu X
    Int J Nanomedicine; 2016; 11():5519-5529. PubMed ID: 27799773
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of Topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization.
    Romero A; Martín M; Cheang MC; López García-Asenjo JA; Oliva B; He X; de la Hoya M; García Sáenz JÁ; Arroyo Fernández M; Díaz Rubio E; Perou CM; Caldés Llopis T
    Am J Pathol; 2011 Apr; 178(4):1453-60. PubMed ID: 21435434
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Promoter polymorphisms of TOP2A and ERCC1 genes as predictive factors for chemotherapy in non-small cell lung cancer patients.
    Grenda A; Błach J; Szczyrek M; Krawczyk P; Nicoś M; Kuźnar Kamińska B; Jakimiec M; Balicka G; Chmielewska I; Batura-Gabryel H; Sawicki M; Milanowski J
    Cancer Med; 2020 Jan; 9(2):605-614. PubMed ID: 31797573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TOP2A, HELLS, ATAD2, and TET3 Are Novel Prognostic Markers in Renal Cell Carcinoma.
    Chen D; Maruschke M; Hakenberg O; Zimmermann W; Stief CG; Buchner A
    Urology; 2017 Apr; 102():265.e1-265.e7. PubMed ID: 28069330
    [TBL] [Abstract][Full Text] [Related]  

  • 36. LncRNA FAM230B Promotes Gastric Cancer Growth and Metastasis by Regulating the miR-27a-5p/TOP2A Axis.
    Cui Y; Pu R; Ye J; Huang H; Liao D; Yang Y; Chen W; Yao Y; He Y
    Dig Dis Sci; 2021 Aug; 66(8):2637-2650. PubMed ID: 32910366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TOP2A and CENPF are synergistic master regulators activated in cervical cancer.
    Yu B; Chen L; Zhang W; Li Y; Zhang Y; Gao Y; Teng X; Zou L; Wang Q; Jia H; Liu X; Zheng H; Hou P; Yu H; Sun Y; Zhang Z; Zhang P; Zhang L
    BMC Med Genomics; 2020 Oct; 13(1):145. PubMed ID: 33023625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer.
    Wu Y; Han Y; Li Q; Zhang P; Yuan P; Luo Y; Fan Y; Chen S; Cai R; Li Q; Xu H; Wang Y; Ma F; Wang J; Xu B
    Breast Cancer Res Treat; 2022 Jun; 193(2):381-392. PubMed ID: 35297009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of ERCC1, RRM1, TOP1, TOP2A, TYMS, TUBB3, GSTP1 AND BRCA1 mRNA expressions in patients with non-small-cell lung cancer receiving a platinum-based chemotherapy.
    M Tsyganov M; O Rodionov E; M Pevzner A; K Ibragimova M; V Miller S; V Cheremisina O; G Frolova I; A Tuzikov S; V Litviakov N
    J BUON; 2020; 25(4):1728-1736. PubMed ID: 33099907
    [TBL] [Abstract][Full Text] [Related]  

  • 40. TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer.
    Erriquez J; Becco P; Olivero M; Ponzone R; Maggiorotto F; Ferrero A; Scalzo MS; Canuto EM; Sapino A; Verdun di Cantogno L; Bruna P; Aglietta M; Di Renzo MF; Valabrega G
    Gynecol Oncol; 2015 Sep; 138(3):627-33. PubMed ID: 26100858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.